March 5 - 9, 2017
McCormick Place
Chicago, IL, USA

Waters Symposium.

The Twenty-Eighth James L Waters Symposium on Genomic Analysis Technologies.

Genomic Analysis Technologies

The Twenty-Eighth Annual Waters Symposium will recognize the history, science, and applications of the technologies developed by Illumina, Inc., recently ranked 13th on Chemical and Engineering News’ list of top instrument firms in 2015.

The SACP is extremely pleased to welcome the following innovators:

David R. Walt, Tufts University
Jay Flatley, Illumina
Jim Goldberg, Counsyl
Daniel S. Grosu, LabCorp
Alex Aravanis, GRAIL

VIEW SPEAKER BIOS

Symposium Details

Monday, March 6, 1:30 PM

Room: W183c

VIEW SYMPOSIUM ABSTRACTS

About the 2017 Waters Symposium
This prestigious symposium will discuss the history, science, and applications of the technologies developed by Illumina, Inc., recently ranked 13th on Chemical and Engineering News’ list of top instrument firms in 2015.

Illumina has become the market leader in next generation genomics tools transforming our understanding of biology and genetics, as well as the face of healthcare. The road from an academic discovery to the foundations of this transformative company will be described and general lessons will be provided.

What is the Waters Symposium?
The James L. Waters Annual Symposium is a unique component of the Pittsburgh Conference Technical Program. Mr. Waters, founder of Waters Associates, Inc. and President of Waters Business Systems, Inc. proposed in 1989 that the Society for Analytical Chemists of Pittsburgh (SACP) offer an annual symposium exploring the origin, development, implementation, and commercialization of scientific instrumentation of established and major significance. The objective of the symposium is to recognize researchers and the development and application of instrumentation by preserving the early, and in some cases, more mature history of the important contributions as well as the cooperation between inventors, scientists, engineers, entrepreneurs, and marketing organizations.

Symposium Speakers
The SACP is extremely pleased to welcome the following innovators:

David R. Walt, Tufts University

University Professor at Tufts University and is a Howard Hughes Medical Institute Professor. Dr. Walt is the Scientific Founder of both Illumina Inc. and Quanterix Corp and several other companies. He is a member of the National Academy of Engineering.

View Abstract:
Taking a Discovery From an Academic Laboratory and Building a Transformative Company

Jay Flatley, Illumina

Jay Flatley is Executive Chairman of Illumina. He served as President and CEO from 1999 to early 2016, and took the company from $1.3 million in sales in 2000 to over $2.2 billion in 2015. Jay also serves as Chairman of the Board of Helix and Grail.

View Abstract:
Next-Generation Sequencing

Jim Goldberg, Counsyl

Dr. Goldberg is currently the Chief Medical Officer at Counsyl. He is board certified in obstetrics and gynecology, maternal-fetal medicine, and medical genetics. He has served as president of the Perinatal Quality Foundation and on the board of the Society for Maternal Fetal Medicine.

View Abstract:
Application of Next Generation Sequencing to Pan-Ethnic Carrier Screening

Daniel S. Grosu, LabCorp

Daniel S. Grosu has more than 15 years of experience in the Diagnostics space. He was most recently the Chief Medical Officer at Sequenom. Previously, Dr. Grosu served as Illumina’s first Chief Medical Officer; he established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the first FDA clearance and first CE Marking of a next-generation sequencing IVD platform and clinical assay. Earlier in his career, Dr. Grosu held positions of increasing responsibility at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, Missouri, and an MBA from the University of Oxford, UK.

View Abstract:
Non-Invasive Prenatal Testing as the First Major “Liquid Biopsy” Clinical Application

Alex Aravanis, GRAIL

Alex Aravanis heads the research and development group at GRAIL, an Illumina spin-out company based in the San Francisco Bay Area, United States. GRAIL is focused on the development of an early cancer detection test based on deep sequencing of cell-free nucleic acids. Prior to GRAIL, Alex developed multiple products at Illumina, including clinical assays for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics, and liquid biopsy using cell-free nucleic acids. He received his MD and PhD in electrical engineering from Stanford University.

View Abstract:
Circulating Cell-Free Nucleic Acids and Early Cancer Detection

 

 

 

Back to Top